Y Intercept Hong Kong Ltd Boosts Holdings in ADMA Biologics Inc $ADMA

Y Intercept Hong Kong Ltd lifted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 40.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,283 shares of the biotechnology company’s stock after purchasing an additional 30,392 shares during the period. Y Intercept Hong Kong Ltd’s holdings in ADMA Biologics were worth $1,543,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC acquired a new position in ADMA Biologics in the 3rd quarter worth $25,000. Cullen Frost Bankers Inc. increased its position in shares of ADMA Biologics by 112.5% during the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,081 shares during the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of ADMA Biologics in the second quarter worth about $46,000. EverSource Wealth Advisors LLC lifted its stake in shares of ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 2,180 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in ADMA Biologics by 53.6% in the second quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 964 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Up 1.7%

NASDAQ:ADMA opened at $17.30 on Friday. The company has a market cap of $4.12 billion, a PE ratio of 20.12 and a beta of 0.47. The business’s 50 day moving average is $18.57 and its two-hundred day moving average is $17.04. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The business had revenue of $134.22 million during the quarter, compared to the consensus estimate of $131.20 million. During the same period in the previous year, the business earned $0.15 EPS. The business’s quarterly revenue was up 12.0% on a year-over-year basis. On average, analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $28.50.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.